DE59712555D1
(de)
*
|
1996-06-05 |
2006-04-06 |
Roche Diagnostics Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
ATE493998T1
(de)
*
|
1996-08-08 |
2011-01-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische zusammensetzung mit einem exendin-4-peptid
|
JP2001504105A
(ja)
*
|
1996-11-12 |
2001-03-27 |
ノボ ノルディスク アクティーゼルスカブ |
Glp―1ペプチドの利用
|
AU739020B2
(en)
|
1997-01-07 |
2001-10-04 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
US20040022807A1
(en)
*
|
1998-06-05 |
2004-02-05 |
Duft Bradford J |
Methods for treating obesity
|
EP1938831A1
(fr)
*
|
1997-08-08 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Nouveaux composants d'agoniste d'exendine
|
NZ502592A
(en)
*
|
1997-08-08 |
2002-03-28 |
Amylin Pharmaceuticals Inc |
Exendin agonist peptides and their use in the treatment of type I and II diabetes
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
BR9815670A
(pt)
*
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
EP1938830A1
(fr)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Nouveaux composants d'agoniste d'exendine
|
AU2003200129B2
(en)
*
|
1997-11-14 |
2006-06-22 |
Amylin Pharmaceuticals, Llc |
Novel Exendin Agonist Compounds
|
AU2006225176B2
(en)
*
|
1997-11-14 |
2009-01-08 |
Amylin Pharmaceuticals, Llc |
Novel exendin agonist compounds
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
DE69839021T3
(de)
*
|
1997-11-14 |
2013-08-08 |
Amylin Pharmaceuticals, Llc |
Neuartige exendin agonisten
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
EP1941900A1
(fr)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Nouveaux composants d'agoniste d'exendine
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
EP1140145B2
(fr)
*
|
1999-01-14 |
2019-05-15 |
Amylin Pharmaceuticals, LLC |
Nouvelles formulations d'agonistes de l'exendine et modes d'administration
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
DE60032331T2
(de)
*
|
1999-01-14 |
2007-06-21 |
Amylin Pharmaceuticals, Inc., San Diego |
Exendine zur glucagon suppression
|
US20030087820A1
(en)
*
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(fr)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides abaissant le taux de glucose sanguin
|
WO2001051078A1
(fr)
*
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
|
EP1634605A3
(fr)
*
|
2000-03-08 |
2006-10-11 |
Novo Nordisk A/S |
traitement de la dyslipidémie chez un patient souffrant de diabète de type 2
|
AU2002230843B8
(en)
|
2000-12-14 |
2007-05-17 |
Amylin Pharmaceuticals, Llc |
Peptide YY and peptide YY agonists for treatment of metabolic disorders
|
US20090281032A1
(en)
*
|
2001-03-01 |
2009-11-12 |
Peter Raymond Flatt |
Modified CCK peptides
|
CA2455963C
(fr)
|
2001-07-31 |
2017-07-04 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Analogues de peptides glp-1, exendine-4 et ses utilisations
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
ES2320979T3
(es)
*
|
2001-09-24 |
2009-06-01 |
Imperial Innovations Limited |
Pyy-36 para la reduccion o prevencion de la obesidad.
|
WO2003059378A2
(fr)
*
|
2001-12-29 |
2003-07-24 |
Novo Nordisk A/S |
Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
|
AU2003235742B2
(en)
*
|
2002-01-08 |
2008-08-07 |
Amylin Pharmaceuticals, Llc |
Use of Amylin agonists to modulate triglycerides
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
AU2003201998C1
(en)
*
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
AU2003286472A1
(en)
*
|
2002-10-17 |
2004-05-04 |
Alkermes Controlled Therapeutics, Inc. Ii |
Microencapsulation and sustained release of biologically active polypeptides
|
CA2501677A1
(fr)
*
|
2002-10-22 |
2004-05-06 |
Waratah Pharmaceuticals, Inc. |
Traitement du diabete
|
WO2004050115A2
(fr)
*
|
2002-12-03 |
2004-06-17 |
Novo Nordisk A/S |
Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
|
AU2003256988A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
WO2005000222A2
(fr)
*
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
|
EP1663289A2
(fr)
*
|
2003-08-29 |
2006-06-07 |
Amylin Pharmaceuticals, Inc. |
Procedes pour traiter ou ameliorer des maladies et des troubles associes a la ghreline
|
KR101135244B1
(ko)
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
EP1684793B1
(fr)
*
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Composition pharmaceutique comprenant un analogue insulinotrope de glp-1(7-37), de l'insuline-asp(b28), et un surfactant
|
US8263084B2
(en)
*
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
HUE038395T2
(hu)
|
2003-11-20 |
2018-10-29 |
Novo Nordisk As |
Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
|
JP4865565B2
(ja)
*
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN1961000B
(zh)
*
|
2004-02-11 |
2011-05-04 |
安米林药品公司 |
具有可选择特性的杂合多肽
|
US8114958B2
(en)
|
2004-02-11 |
2012-02-14 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides
|
PT2100904E
(pt)
|
2004-04-23 |
2010-09-24 |
Conjuchem Biotechnologies Inc |
Fase sólida para utilização num método para a purificação de conjugados de albumina
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
JP2008501765A
(ja)
*
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1アゴニストを用いた薬剤誘発性肥満の中和
|
WO2007055728A1
(fr)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Traitement de l'obesite et de troubles associes
|
AU2005305036B2
(en)
*
|
2004-11-01 |
2011-03-10 |
Amylin Pharmaceuticals, Llc |
Treatment of obesity and related disorders
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP2127676A3
(fr)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Traitement de l'obésité et les maladies et troubles liés à l'obésité
|
EP1841448A2
(fr)
*
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Compositions pharmaceutiques et procedes pour le retablissement de masse et de fonction de cellule-beta
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(fr)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solutions de solvant/polymere utilisees comme vehicules de suspension
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CA2597649A1
(fr)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
|
EP1888043A4
(fr)
*
|
2005-03-11 |
2010-07-28 |
Endo Pharmaceuticals Solutions |
Preparation d'octreotide a liberation lente
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
US7879794B2
(en)
|
2005-03-31 |
2011-02-01 |
Amylin Pharmaceuticals, Inc. |
Methods for controlling binge eating disorders
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
CA2617649A1
(fr)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Polypeptides hybrides presentant des proprietes selectionnables
|
WO2007022518A2
(fr)
*
|
2005-08-19 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Nouvelles utilisations de proteines glucoregulatoires
|
CA2619426C
(fr)
|
2005-08-19 |
2016-06-21 |
Amylin Pharmaceuticals, Inc. |
Utilisation d'exendines pour le traitement du diabete et la reduction de la masse corporelle
|
CA2625416A1
(fr)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combinaison de composes organiques
|
WO2007055743A2
(fr)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Procédés pour traiter l'obésité et des troubles associés
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
WO2007064124A1
(fr)
*
|
2005-11-29 |
2007-06-07 |
Kolon Industries, Inc |
Membrane a fibres creuses composites renforcees par une tresse
|
US20070269863A1
(en)
*
|
2005-12-22 |
2007-11-22 |
Bridon Dominique P |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
EP2035450A2
(fr)
|
2006-05-26 |
2009-03-18 |
Amylin Pharmaceuticals, Inc. |
Composition et procédés de traitement de l'insuffisance cardiaque globale
|
AU2007266475B2
(en)
|
2006-05-30 |
2009-12-03 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
WO2008012629A2
(fr)
|
2006-07-24 |
2008-01-31 |
Biorexis Pharmaceutical Corporation |
Protéines de fusion d'extendine
|
EP2068910A2
(fr)
*
|
2006-08-04 |
2009-06-17 |
Amylin Pharmaceuticals, Inc. |
Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
|
US8501693B2
(en)
*
|
2006-08-04 |
2013-08-06 |
Amylin Pharmaceuticals, Llc |
Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
|
DK2049081T3
(da)
|
2006-08-09 |
2013-02-25 |
Intarcia Therapeutics Inc |
Osmotiske leveringssystemer og stempelarrangementer
|
US20100227809A1
(en)
*
|
2006-08-17 |
2010-09-09 |
Wellstat Therapeutics Corporation |
Combination treatment for metabolic disorders
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
EP2057189B1
(fr)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Composés d'exendine-4 acylée
|
KR100872304B1
(ko)
*
|
2006-11-28 |
2008-12-05 |
주식회사 코오롱 |
편물로 보강된 복합 중공사막
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
PT2157967E
(pt)
*
|
2007-04-23 |
2013-04-03 |
Intarcia Therapeutics Inc |
Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
EA201070609A1
(ru)
*
|
2007-11-14 |
2010-12-30 |
Амилин Фармасьютикалз, Инк. |
Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
|
JP2011506442A
(ja)
*
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
WO2009109927A2
(fr)
*
|
2008-03-05 |
2009-09-11 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
|
WO2009143285A2
(fr)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendines pour diminuer le cholestérol et les triglycérides
|
JP5622725B2
(ja)
*
|
2008-06-25 |
2014-11-12 |
エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド.Endo Pharmaceuticals Solutionsinc. |
エキセナチド及び他のポリペプチド類の持続的送達
|
AU2009262263B2
(en)
*
|
2008-06-25 |
2014-08-14 |
Endo Pharmaceuticals Solutions Inc. |
Octreotide implant having a release agent
|
JP2011528709A
(ja)
*
|
2008-07-21 |
2011-11-24 |
トランスファーマ メディカル リミテッド |
インクレチンおよびインクレチン模倣ペプチドの持続性送達用経皮システム
|
CN104248623B
(zh)
|
2008-09-04 |
2020-04-03 |
安米林药品有限责任公司 |
使用非水性载体的持续释放制剂
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
CA2740685C
(fr)
|
2008-10-17 |
2018-09-11 |
Sanofi-Aventis Deutschland Gmbh |
Combinaison d'une insuline et d'un agoniste de glp-1
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
WO2010096394A2
(fr)
*
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
EP2435061A4
(fr)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
Composés agonistes du récepteur glp-1 pour amélioration du sommeil
|
KR102148624B1
(ko)
|
2009-09-28 |
2020-08-26 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
EP2496249B1
(fr)
*
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Agoniste du récepteur du glp-1 pour l'utilisation dans le traitement de l'apnée obstructive du sommeil
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
JP5973918B2
(ja)
|
2009-11-13 |
2016-08-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト及びメチオニンを含む薬学的組成物
|
CN102770152B
(zh)
|
2009-11-25 |
2016-07-06 |
阿瑞斯根股份有限公司 |
肽类的粘膜递送
|
CN102100912B
(zh)
*
|
2009-12-16 |
2015-04-22 |
上海蓝心医药科技有限公司 |
一种给药组合物及其制备和使用方法
|
WO2011123943A1
(fr)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
|
NZ603169A
(en)
|
2010-04-27 |
2015-02-27 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
MX345245B
(es)
|
2010-09-28 |
2017-01-23 |
Amylin Pharmaceuticals Llc |
Polipeptidos manipulados que tienen duracion de accion incrementada.
|
WO2012088157A2
(fr)
|
2010-12-22 |
2012-06-28 |
Amylin Pharmaceuticals, Inc. |
Agonistes du récepteur de glp-1 pour une transplantation de cellules d'îlot
|
CA2824143C
(fr)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Immunoglobulines polypeptidiques a marquage aldehydique et leur methode d'utilisation
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
ES2664873T3
(es)
|
2011-03-01 |
2018-04-23 |
Synergy Pharmaceuticals Inc. |
Proceso de preparación de agonistas de guanilato ciclasa C
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2012162547A2
(fr)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Conjugués de deux hormones longue durée
|
ES2634716T3
(es)
|
2011-05-31 |
2017-09-28 |
Celgene International Ii Sàrl |
Nuevos estabilizantes y moduladores del receptor GLP-1
|
JP6396211B2
(ja)
|
2011-07-04 |
2018-09-26 |
インペリアル・イノベイションズ・リミテッド |
新規化合物及び摂食行動に対するそれらの効果
|
WO2013009545A1
(fr)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
DK2763690T3
(en)
|
2011-10-04 |
2016-02-15 |
Sanofi Aventis Deutschland |
LIXISENATID TO USE FOR TREATMENT OF STENOSIS AND / OR OBSTRUCTION IN THE PANCREASURAL SYSTEM
|
WO2013050378A1
(fr)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Agoniste du glp-1 pour l'utilisation dans le traitement de la sténose et/ou de l'obstruction dans le tractus biliaire
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
US8778923B2
(en)
|
2011-12-12 |
2014-07-15 |
Receptos, Inc. |
GLP-1 receptor modulators
|
AR091422A1
(es)
|
2012-06-14 |
2015-02-04 |
Sanofi Sa |
Analogos peptidicos de la exendina 4
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
RU2652783C2
(ru)
|
2012-12-21 |
2018-05-03 |
Санофи |
Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
|
KR101581497B1
(ko)
|
2013-01-24 |
2015-12-30 |
강원대학교산학협력단 |
인삼열매 추출물을 포함하는 파킨슨병과 알츠하이머병의 예방 또는 치료용 조성물
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
JP6368722B2
(ja)
|
2013-03-01 |
2018-08-01 |
フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ |
網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
BR112015031040A8
(pt)
|
2013-06-11 |
2018-01-02 |
Receptos Inc |
Novos moduladores do receptor de glp-1
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
SG11201602965WA
(en)
|
2013-10-17 |
2016-05-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
RU2016117275A
(ru)
|
2013-11-01 |
2017-12-04 |
Сфериум Биомед С.Л. |
Тельца включения для трансдермальной доставки терапевтических и косметических средств
|
TR201902516T4
(tr)
|
2013-11-06 |
2019-03-21 |
Zealand Pharma As |
Glukagon-glp-1-gıp üçlü agonist bileşikleri.
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
WO2015086728A1
(fr)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
WO2015086729A1
(fr)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Agonistes mixtes des récepteurs glp-1/gip
|
JP6723921B2
(ja)
|
2014-01-09 |
2020-07-15 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
EA032525B1
(ru)
|
2014-07-25 |
2019-06-28 |
Селджин Интернэшнл Ii Сарл |
Модуляторы рецептора glp-1
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
DK3186242T3
(da)
|
2014-08-29 |
2021-12-20 |
Tes Pharma S R L |
Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
EP3212218B1
(fr)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Composés agonistes de gip et procédés associés
|
MX2017007494A
(es)
|
2014-12-10 |
2017-10-31 |
Celgene Int Ii Sarl |
Moduladores del receptor de peptido 1 tipo glucagon.
|
HRP20230470T1
(hr)
|
2014-12-12 |
2023-07-21 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija fiksnog omjera inzulin glargin/liksisenatid
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN107636010B
(zh)
|
2015-04-16 |
2021-10-01 |
西兰制药公司 |
酰化胰高血糖素类似物
|
BR112017024997A2
(pt)
|
2015-05-22 |
2018-07-31 |
The Bot Of The Leland Stanford Junior University |
tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
|
KR20240042548A
(ko)
|
2015-06-03 |
2024-04-02 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
CN108138563B
(zh)
*
|
2015-10-01 |
2021-09-21 |
斯伦贝谢技术有限公司 |
用于核磁共振测井工具的有源阻尼
|
WO2017066454A2
(fr)
|
2015-10-14 |
2017-04-20 |
X-Therma, Inc. |
Compositions et procédés permettant de réduire la formation de cristaux de glace
|
CR20180378A
(es)
|
2015-12-23 |
2018-12-06 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
|
US10653753B2
(en)
|
2016-03-04 |
2020-05-19 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
WO2017181007A1
(fr)
*
|
2016-04-15 |
2017-10-19 |
Robert Doyle |
Amélioration d'un médicament peptidique utilisant des conjugués de vitamine b12 et d'un substrat de liaison de l'haptocorrine
|
KR20180135458A
(ko)
|
2016-04-26 |
2018-12-20 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
항체 컨쥬게이트 및 이의 제조 및 이용 방법
|
CN109310743A
(zh)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
胰高血糖素受体选择性多肽及其使用方法
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
EP3515408A1
(fr)
|
2016-09-23 |
2019-07-31 |
Delpor, Inc. |
Compositions stables pour composés mimétiques de l'incrétine
|
EP3526199B1
(fr)
|
2016-10-14 |
2022-04-13 |
Tes Pharma S.r.l. |
Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
|
US11020484B2
(en)
|
2016-11-21 |
2021-06-01 |
Eiger Biopharmaceuticals, Inc. |
Buffered formulations of exendin (9-39)
|
WO2018104263A1
(fr)
|
2016-12-06 |
2018-06-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin
|
CN117384274A
(zh)
|
2016-12-09 |
2024-01-12 |
西兰制药公司 |
酰化的glp-1/glp-2双重激动剂
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
KR20200019122A
(ko)
|
2017-06-20 |
2020-02-21 |
암젠 인크 |
Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
HUE059777T2
(hu)
|
2018-04-10 |
2022-12-28 |
Sanofi Aventis Deutschland |
Lixiszenatid szintézise lánczárással
|
WO2019197466A1
(fr)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Procédé de clivage de peptides liés à une phase solide à partir de la phase solide
|
AR117122A1
(es)
|
2018-11-20 |
2021-07-14 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
AU2020233876A1
(en)
|
2019-03-08 |
2021-09-23 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|